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Osteopenia and bone fractures are significant causes of morbidity in children with cholestatic liver disease. Dual-
energy X-ray absorptiometry (DXA) analysis was performed in children with intrahepatic cholestatic diseases who 
were enrolled in the Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis in the Childhood Liver 
Disease Research Network. DXA was performed on participants aged >5 years (with native liver) diagnosed with 
bile acid synthetic disorder (BASD), alpha-1 antitrypsin deficiency (A1AT), chronic intrahepatic cholestasis (CIC), 
and Alagille syndrome (ALGS). Weight, height, and body mass index Z scores were lowest in CIC and ALGS. 
Total bilirubin (TB) and serum bile acids (SBA) were highest in ALGS. Bone mineral density (BMD) and bone 
mineral content (BMC) Z scores were significantly lower in CIC and ALGS than in BASD and A1AT (P < 0.001). 
After anthropometric adjustment, bone deficits persisted in CIC but were no longer noted in ALGS. In ALGS, 
height-adjusted and weight-adjusted subtotal BMD and BMC Z scores were negatively correlated with TB (P < 
0.001) and SBA (P = 0.02). Mean height-adjusted and weight-adjusted subtotal BMC Z scores were lower in ALGS 
participants with a history of bone fractures. DXA measures did not correlate significantly with biliary diversion 
status. Conclusion: CIC patients had significant bone deficits that persisted after adjustment for height and weight 
and generally did not correlate with degree of cholestasis. In ALGS, low BMD and BMC reference Z scores were 
explained by poor growth. Anthropometrically adjusted DXA measures in ALGS correlate with markers of choles-
tasis and bone fracture history. Reduced bone density in this population is multifactorial and related to growth, 
degree of cholestasis, fracture vulnerability, and contribution of underlying genetic etiology. (Hepatology 2019; 
69:245-257).
Reduced bone density is a common complica-tion of chronic liver disease in both adults and children. Factors contributing to bone mineral 
deficits are dependent on the physiology and severity 
of the underlying liver disease and may include chronic 
nutrient and calcium malabsorption leading to mal-
nutrition and growth failure, deficiencies of fat-solu-
ble vitamins, level of physical activity, and circulating 
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inflammatory cytokines. High rates of osteoporosis 
and bone fracture have been observed in adults with 
chronic cholestatic liver diseases, such as primary 
sclerosing cholangitis (PSC) and primary  biliary 
cholangitis (PBC), and cirrhosis of any cause.(1-3)
Metabolic bone disease is also common in children 
with chronic cholestasis or end-stage liver disease, but 
fewer studies have been conducted to characterize the 
bone mineral deficits in this vulnerable population.
Osteopenia and pathologic fractures have been 
reported in children with chronic cholestatic liver 
disease, including Alagille syndrome (ALGS), pro-
gressive familial intrahepatic cholestasis (PFIC), and 
biliary atresia.(4-7) In some cases, bone disease can 
be severe enough to be an indication for liver trans-
plantation. In contrast to what is seen in adults, chil-
dren have remarkable improvement in bone mineral 
density (BMD) by 1 year after liver transplantation, 
often accompanied by significant catch-up growth.(8,9) 
Despite the impact of metabolic bone disease on 
morbidity and quality of life in pediatric patients 
with chronic liver disease, few detailed studies have 
been done to quantify bone deficits and identify risk 
factors for osteopenia and fracture. In one published 
study, ALGS patients (n = 31) and 80 healthy con-
trol participants underwent evaluation by dual-energy 
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X-ray absorptiometry (DXA). The ALGS children 
were small for age and had reduced bone mineral 
content (BMC) for age and BMC for height, with 
bone mineralization positively related to coefficient of 
fat absorption but not to dietary intake.(10) In another 
study of 16 nonjaundiced children with biliary atre-
sia, whole-body and lumbar spine BMC values were 
found to decline with age, indicating that children 
surviving with native liver are at risk of compromised 
bone health, even in the absence of elevated bilirubin 
levels.(11) To date, there have been no published stud-
ies of DXA analysis in children with other inherited 
chronic liver diseases, such as alpha-1 antitrypsin defi-
ciency (A1AT) or PFIC.
The Childhood Liver Disease Research Network 
(ChiLDReN) is a National Institutes of Health–
funded consortium of pediatric centers in North 
America focused on the study of rare pediatric liver 
diseases. The Longitudinal Study of Genetic Causes 
of Intrahepatic Cholestasis (LOGIC; NCT00571272) 
enrolled children with one of four diagnoses: ALGS, 
PFIC, A1AT, or bile acid synthetic disorder (BASD). 
As part of the LOGIC study protocol, participants 
aged >5 years underwent DXA scanning, the results of 
which are reported here. The objectives of this study 
were to address an important knowledge gap by inves-
tigating the prevalence of bone mineral deficits in this 
cohort of children with chronic liver disease and to 
determine factors associated with lower bone density, 
including growth parameters, laboratory values, and 
clinical events such as fracture and biliary diversion.
Participants and Methods
stUDy DesIgN aND 
paRtICIpaNts
Participants in this study were enrolled in the 
LOGIC study (NCT00571272) through the 
National Institute of Diabetes and Digestive and 
Kidney Diseases–funded multicenter ChiLDReN 
consortium. The study protocol was approved by the 
institutional review boards at each participating cen-
ter and conformed to the ethical guidelines of the 
1975 Declaration of Helsinki. Informed consent was 
obtained from parents or guardians or participants 18 
years or older, and assent was obtained from partici-
pants >7 years of age, per local guidelines.
LOGIC is a longitudinal study designed to inves-
tigate the natural history of several genetic causes 
of cholestasis, including ALGS, A1AT, BASD, and 
PFIC. Children and young adults with a confirmed 
diagnosis of ALGS, A1AT, BASD, or PFIC were eli-
gible for enrollment in LOGIC from birth through 
25 years of age. Detailed enrollment criteria for each 
disease group are presented in Supporting Table S1. 
In the PFIC group, 20 of 41 participants had a con-
firmed genetic diagnosis: 10 with mutations in ade-
nosine triphosphatase phospholipid transporting 8B1 
(ATP8B1), 4 with adenosine triphosphate–binding 
cassette subfamily B member 11 (ABCB11), and 6 
with ABCB4. Because not all of the participants in 
the PFIC group have a documented genetic diagnosis, 
for the purpose of this study, we categorized them as 
chronic intrahepatic cholestasis (CIC).
In the LOGIC protocol, defined data elements, 
including clinical events, laboratory values, growth 
parameters, physical examination findings, and his-
tory and location of bone fractures, were collected at 
enrollment and at yearly visits for 10 years or until 
liver transplantation or death. LOGIC participants 
aged >5 years with their native livers were eligible to 
undergo DXA once during the course of the study. 
DXA scans were performed at 12 ChiLDReN centers 
from 2008 through 2013 (2008-2013 for ALGS and 
CIC participants, 2008-2011 for A1AT, and 2010 for 
BASD). Interim analysis in 2011 revealed minimal 
DXA abnormalities in A1AT and BASD participants, 
so DXA scanning was discontinued in those cohorts 
at that time. DXA results reported here include those 
for participants with ALGS (n = 49), A1AT (n = 44), 
BASD (n = 14), or CIC (n = 41). Supporting Fig. S1 
shows the derivation of the sample population.
DXa measURemeNts
DXA scanning of the whole body, spine, and femur 
was performed using Hologic (Newark, DE) or 
Lunar (GE Health Sciences, Pittsburgh, PA) equip-
ment. DXA equipment for each brand was standard-
ized using BMIL phantoms provided by the DXA 
Coordinating Center.(12) The same phantom was 
used for longitudinal drift correction where necessary. 
Adjustment between the two brands of scanners was 
performed with patient-based correction formulas.(13) 
Standard Z scores were calculated based on age, 
sex, and race reference data.(14) In addition to these 
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analyses, adjusted Z scores were calculated based on 
age, sex, race, height, and weight.(15) For a special, 
supplementary analysis, adjusted Z scores with all 
of the above listed parameters and percent body fat 
were also calculated.(15) In most cases, anthropometric 
measurements were obtained on the same day as the 
DXA scan; otherwise, the measurements closest to the 
date of scan were used.
statIstICal metHoDs
The preplanned analyses of the DXA data included 
all LOGIC participants with their native liver for 
whom a DXA was performed. Descriptive statistics 
are displayed as means and standard deviations or 
median with first and third quartiles for continu-
ous variables and as frequencies and percentages for 
categorical variables. Winsorizing refers to a statisti-
cal technique in which extreme values are limited in 
order to reduce the effect of possibly spurious outli-
ers.(16) To reduce the influence of outliers, all DXA 
Z scores were Winsorized using a lower limit of –3 
and an upper limit of 3. All DXA Z scores presented 
are adjusted for age, sex, race (black versus nonblack), 
weight, and height, unless otherwise indicated.
We characterized DXA Z scores in two ways—as 
a continuous variable and as a dichotomous variable 
based on the proportion of participants <–1.5 versus 
>–1.5. Comparisons of DXA Z scores and other con-
tinuous variables among diagnosis groups were tested 
using analysis of variance (ANOVA) (or by non-
parametric Kruskal-Wallis tests if the distributional 
assumptions of ANOVA were not met), and compar-
isons of dichotomous DXA Z scores and other cate-
gorical variables, by diagnosis group, were tested with 
chi-squared tests. Within diagnosis groups, differ-
ences in laboratory values between participants with 
DXA Z scores <–1.5 versus >–1.5 and differences in 
DXA Z scores for participants with and without bone 
fractures and with and without biliary diversion were 
compared using two-sample t tests.
Pearson correlation coefficients and their corre-
sponding P values were used to examine associa-
tions between participant anthropometric parameters 
(height, weight, and body mass index [BMI] Z scores) 
and reference DXA Z scores (defined as the standard 
method to adjust for age, sex, and race) and between 
DXA Z score and laboratory values. Laboratory values 
were obtained within 1 year of DXA scan. Height, 
weight, and BMI Z scores were calculated based on 
Centers for Disease Control and Prevention growth 
charts (reference year 2000; https://www.cdc.gov/
nccdphp/dnpao/growthcharts/resources/sas.htm). 
Statistical analyses were carried out using SAS ver-
sion 9.4 (SAS Institute, Cary, NC). Due to the large 
number of comparisons being made, we considered P 
values <0.01 to be statistically significant.
Results
CHaRaCteRIstICs oF stUDy 
CoHoRt
Our study cohort consisted of a total of 148 par-
ticipants enrolled in the LOGIC study as part of the 
ChiLDReN consortium. Supporting Fig. S1 shows 
the derivation of the study population. Participants 
had ALGS (n = 49), CIC (n = 41), A1AT (n = 
44), or BASD (n = 14). Table 1 displays character-
istics of participants in the study by disease group. 
The A1AT and BASD groups had higher percent-
ages of male participants than the ALGS and CIC 
groups: 70% and 79% versus 57% and 44%, respec-
tively. Participants were similar across disease groups 
for race, ethnicity, and age. The rate of bone frac-
ture occurrence was not statistically different among 
disease groups. Anthropomorphic measurements 
were significantly different across disease groups (P 
< 0.001), with ALGS and CIC participants having 
lower mean height, weight, and BMI Z scores than 
participants with A1AT or BASD. Nonparametric 
Kruskal-Wallis tests confirmed results from ANOVA 
(data not shown). Across all disease groups, few par-
ticipants had a BMI Z score <–2. The mean percent-
ages of lean body mass were similar among disease 
groups, ranging from 74% to 76% (Table 1).
Mean laboratory measurements of bilirubin, gam-
ma-glutamyl transpeptidase, alkaline phosphatase, 
alanine aminotransferase, aspartate aminotransferase, 
and serum bile acids (SBAs) were highest in partici-
pants with ALGS, intermediate for those with CIC, 
and lowest in participants with A1AT and BASD. 
Mean albumin and hemoglobin were lower in ALGS 
and CIC compared with A1AT and BASD. There 
were no statistical differences in international normal-
ized ratio (INR), white blood cell count, and platelet 
count between groups. Few participants met criteria 
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for portal hypertension as defined by spleen size >2 
cm below the left costal martin and platelet count 
<150,000/µL,(17) with no significant differences across 
disease groups (Table 1).
Overall, LOGIC participants who underwent DXA 
scanning were similar to those who did not, with a 
few exceptions. Supporting Table S2 shows demo-
graphic and clinical characteristics of participants who 
were eligible but did not undergo DXA scan. In the 
BASD group, some differences were identified in sex, 
race, and ethnicity between participants who did (n = 
14) and did not (n = 7) undergo DXA. The mean age 
tended to be younger in the non-DXA participants. 
In the CIC group, participants who underwent DXA 
had lower weight and BMI Z scores. In the ALGS 
and CIC groups, DXA study participants had higher 
25-hydroxyvitamin (OH) vitamin D levels than those 
who did not undergo DXA scanning. Minor differ-
ences in hemoglobin were also identified in the BASD 
and A1AT groups.
DXa sCoRes
The A1AT and BASD participants did not have 
significant bone mineral deficits as measured by 
DXA (Supporting Table S3); therefore, the results are 
focused on the ALGS and CIC groups. Table 2 shows 
summary measures of reference as well as height-ad-
justed and weight-adjusted BMD and BMC Z scores 
resulting from DXA scans by disease group for ALGS 
and CIC participants. The reference scores take into 
account the participants’ age, sex, and race. Mean 
DXA reference Z scores were similar between ALGS 
and CIC participants, except for spine BMD, which 
was lower in the CIC group (Table 2). Because some 
of the children in the study cohort have significant 
growth deficits, we examined correlations between 
DXA reference Z scores and height, weight, and 
BMI Z scores by disease group (Table 3). All DXA 
reference Z scores correlated strongly with height Z 
taBle 2. DXa Reference and Height-adjusted and Weight-adjusted Z scores by Disease group
Mean (SD) % with Z <–1.5 ALGS (n = 46-49) CIC (n = 39-41) P* Winsorized† Values, n (%)
BMD measures
Total body minus head
Reference Z score –1.10 (1.57) 46.9% –1.58 (1.11) 56.1% 0.10 13 (14%)
Adjusted Z score 0.23 (1.65) 20.8% –0.37 (1.45) 20.0% 0.07 9 (10%)
Spine
Reference Z score –0.08 (1.66) 20.4% –1.01 (1.36) 43.9% 0.005 9 (10%)
Adjusted Z score 0.13 (1.65) 20.8% –1.15 (0.98) 40.0% <0.001 4 (5%)
Total hip
Reference Z score –0.78 (1.38) 23.4% –1.17 (1.23) 47.5% 0.16 10 (11%)
Adjusted Z score –0.46 (1.41) 21.7% –1.17 (1.30) 43.6% 0.02 7 (8%)
BMC measures
Total body minus head
Reference Z score –1.23 (1.45) 44.9% –1.80 (1.33) 63.4% 0.06 25 (28%)
Adjusted Z score 0.36 (1.34) 10.4% –0.76 (1.16) 27.5% <0.001 7 (8%)
Tests for differences DXA Z scores between disease groups were performed using two-sample t tests.
†Values <–3 were set to –3, and values >3 were set to 3.
taBle 3. pearson Correlations Between DXa Reference  
Z scores* and Height, Weight, and BmI Z scores for algs 
and CIC
ALGS (n = 47-49) CIC (n = 40-41)
Height Weight BMI Height Weight BMI
BMD measures
Total body 0.62§ 0.53§ 0.18 0.56‡ 0.55‡ 0.23
Total body minus head 0.67§ 0.59§ 0.24 0.59§ 0.55‡ 0.19
Spine 0.58§ 0.44† 0.09 0.53‡ 0.54‡ 0.29
Total hip 0.57§ 0.48‡ 0.19 0.33 0.32 0.18
Hip neck 0.56§ 0.42† 0.16 0.33 0.35 0.24
BMC measures
Total body 0.76§ 0.69§ 0.34 0.73§ 0.68§ 0.28
Total body minus head 0.81§ 0.73§ 0.34 0.74§ 0.68§ 0.27
*Reference Z score is adjusted for age, sex, and race (black versus 
nonblack).
†P < 0.01.
‡P < 0.001.
§P < 0.0001.
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scores in the ALGS participants (P < 0.0001). In the 
ALGS group, weight Z scores also correlated strongly 
with total body and total body minus head BMD and 
BMC DXA reference Z scores (P < 0.0001) and, to a 
lesser extent with spine, total hip, and hip neck DXA 
reference Z scores (Table 3). Height and weight Z 
scores for the CIC participants correlated with total 
body and total body minus head BMD and BMC 
DXA reference Z scores. Fewer correlations were 
identified in A1AT and BASD (Supporting Table 
S4), but these participants also did not have signif-
icant growth deficits at the time of DXA (Table 1). 
No correlations were found between DXA reference 
Z scores and BMI Z scores for any disease group. 
Because DXA reference Z scores were so tightly cor-
related with growth parameters, we elected to adjust 
all DXA Z scores for weight and height according to 
the method of Short et al.(15)
After adjustment for height and weight, mean total 
body minus head BMD and BMC Z scores were higher 
(than when calculated with the reference methods) in 
both ALGS and CIC groups, indicating that these bone 
deficits are at least in part due to small size (Table 2). 
Interestingly, the CIC group had deficits in total spine 
and total hip BMD reference Z scores that persisted 
after adjustment for height and weight, with total spine 
and total hip BMD Z scores in the CIC group of –1.15 
and –1.17, respectively. Over 40% of the CIC cohort 
had a Z score <–1.5, in contrast to the expected distri-
bution of 7% for the reference population.
Fig. 1 displays the reference and adjusted Z scores 
for total body minus head BMD and BMC for the 
FIg. 1. Comparison between DXA reference and height-adjusted and weight-adjusted Z scores for total body minus head measurements 
(top, BMD; bottom, BMC) for the ALGS and CIC disease groups. The reference line indicates equality between the reference and 
adjusted Z scores. Points above the line indicate observations where the Z score adjusted for height and weight is higher than the 
reference Z score. Points below the line indicate observations where the adjusted Z score is lower than the reference Z score. *Non-
Winsorized BMD values presented.
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ALGS and CIC groups (results for A1AT and BASD 
disease groups are shown in Supporting Fig. S2). For 
both the ALGS and CIC disease groups, the data 
indicate that low weight and height for age contribute 
to observed bone mineral deficits. Supporting Table S3 
shows data for additional DXA measurements (total 
body and hip neck) and all DXA measurements for 
the A1AT and BASD disease groups. All DXA mea-
sures are also presented with adjustment for weight, 
height, and percent body fat (Supporting Table S3). 
Of note, differences in DXA Z scores among body 
areas are not unexpected due to intrinsic differences in 
cortical and trabecular bone composition.
assoCIatIoNs BetWeeN 
DXa aND laBoRatoRy 
measURemeNts
We examined potential associations between DXA 
height-adjusted and weight-adjusted Z scores and 
laboratory measurements using Pearson correlation 
coefficients. The correlations for ALGS and CIC are 
shown in Table 4. In ALGS participants, all of the 
height-adjusted and weight-adjusted BMD and BMC 
measures were negatively correlated with serum total 
bilirubin (TB; P < 0.001). In the ALGS group, many 
of the DXA measurements were also correlated with 
INR and albumin. There were no significant correla-
tions found in the CIC (Table 4), A1AT, or BASD 
groups (data not shown).
Supporting Table S5 compares mean lab values 
for ALGS and CIC participants with DXA Z scores 
above and below –1.5. There were no significant dif-
ferences found in the CIC group. In ALGS, albumin 
was lower in participants with height-adjusted and 
weight-adjusted BMD Z scores <–1.5 compared with 
those ≥–1.5.
DIFFeReNCes IN DXa Z sCoRes 
By BoNe FRaCtURe aND 
BIlIaRy DIVeRsIoN
Table 5 shows differences in DXA height-ad-
justed and weight-adjusted Z scores, TB, and SBAs 
by whether or not the participant had a bone frac-
ture. There were no significant differences seen for 
any of the DXA measurements or the lab values in 
the CIC group. In ALGS, adjusted spine BMD and 
total body minus head BMC Z scores were lower in 
the fracture group (–0.6 versus 0.6, P = 0.02; and 
–0.2 and 0.7, P = 0.02). Serum TB and SBAs were 
both higher in the fracture group (6.1 versus 2.0, 
P = 0.03; and 157 versus 80, P = 0.02) for ALGS 
participants. However, the P value of 0.02 for these 
comparisons does not meet our cutoff for statistical 
significance of P < 0.01.
We also examined DXA scores by biliary diver-
sion status. There were 9 (18%) ALGS partic-
ipants with a biliary diversion performed prior to 
the DXA scan. The median time between diversion 
and the DXA scan was 7 years. The CIC group had 
23 (56%) participants with a biliary diversion per-
formed prior to the DXA scan. The median time 
between diversion and DXA was 6 years. Table 6 
taBle 4. pearson Correlations Between DXa Height-adjusted and Weight-adjusted Z scores and laboratory measures of 
Cholestasis and liver synthetic Function
ALGS (n = 37-47*) CIC (n = 32-40*)
TB 
(mg/dL)
SBA 
(µmol/L)
Vitamin D 
(ng/mL) INR
Albumin 
(g/dL)
TB 
(mg/dL)
SBA 
(µmol/L)
Vitamin D 
(ng/mL) INR
Albumin 
(g/dL)
BMD
Total body minus head –0.54‡ –0.37 0.07 –0.41† 0.35 –0.12 –0.29 0.19 0.08 –0.08
Spine –0.59§ –0.31 0.27 –0.33 0.44† –0.36 –0.29 0.09 0.00 0.20
Total hip –0.66§ –0.36 0.14 –0.44† 0.53‡ –0.24 –0.09 0.03 0.13 0.22
BMC
Total body minus head –0.63§ –0.39 0.33 –0.31 0.48‡ –0.39 –0.23 –0.09 0.01 0.29
*Number of participants varies due to missing values for DXA or lab measurements.
†P < 0.01.
‡P < 0.001.
§P < 0.0001.
Abbreviations: INR, international normalized ratio.
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shows mean DXA height-adjusted and weight-ad-
justed Z scores for ALGS and CIC by the diversion 
status. The spine DXA Z score was lower in ALGS 
participants with biliary diversion compared to those 
without (–1.1 versus 0.4, P = 0.013). In participants 
with CIC, the mean total body minus head BMD Z 
score was higher in the diversion group (0.1 versus 
–1.0, P = 0.03). However, these differences did not 
reach the threshold of P < 0.01 for statistical signif-
icance in this study.
Discussion
In this multicenter study, we report the results of 
DXA analysis in children with four types of intrahe-
patic cholestasis—ALGS, CIC (including genetically 
determined PFIC), A1AT, and BASD. Importantly, 
participants with A1AT or BASD did not have mean-
ingful bone mineral deficits detected by DXA, but 
these participants were also only mildly cholestatic 
at the time of the DXA scan (Table 1). In contrast, 
study participants with ALGS and CIC had signif-
icant bone mineral deficits that correlated strongly 
with growth parameters. Adjustment for height and 
weight normalized DXA BMD and BMC Z scores 
in ALGS but to a lesser extent in CIC. In ALGS, 
weight-adjusted and height-adjusted DXA Z scores 
correlated with laboratory indicators of cholestasis 
and hepatic synthetic function. Bone fracture occur-
rence correlated with DXA parameters and lab val-
ues in the ALGS group, who were prone to fractures. 
In this cohort, biliary diversion did not have a major 
impact on DXA Z scores.
DXA is a two-dimensional projection technique 
that summarizes total bone mass within the projected 
bone area. This measurement of areal BMD (grams 
per square centimeter) is known to systematically 
underestimate volumetric BMD (grams per cubic cen-
timeter) in children with poor growth,(18) and various 
methods have been used to adjust for body size.(19) 
In light of this intrinsic limitation of DXA analysis 
and the fact that in our study cohort we observed a 
strong correlation between DXA measurements and 
anthropometrics (Table 3), we elected to adjust for 
height and weight using the method of Short et al.(15) 
taBle 6. Differences in DXa Height-adjusted and 
Weight-adjusted Z score measures by Biliary Diversion*
ALGS (n = 49) CIC (n = 41)
n Mean (SD) P† n Mean (SD) P†
BMD
Total body minus head 0.34 0.03
Diversion 9 –0.2 (1. 9) 23 0.1 (1.5)
No diversion 39 0.4 (1.6) 17 –1.0 (1.2)
Spine 0.013 0.90
Diversion 9 –1.1 (1. 5) 23 –1.1 (1.0)
No diversion 39 0.4 (1.6) 17 –1.2 (1.0)
Total hip 0.10
Diversion 9 –1.1 (1.1) 22 –1.0 (1.4) 0.40
No diversion 37 –0.3 (1.4) 17 –1.4 (1.1)
BMC
Total body minus head 0.13 0.65
Diversion 9 –0.2 (1.5) 23 –0.7 (1.2)
No diversion 39 0.5 (1.3) 17 –0.9 (1.2)
*All diversions were performed prior to DXA scans. The median 
(interquartile range) times between diversion and scan for ALGS 
and CIC were 7 (7-10) and 6 (5-10) years, respectively.
†P value based on two-sample t test.
taBle 5. Differences in DXa Height-adjusted and 
Weight-adjusted Z score measures and lab Values by 
occurrence of Bone Fracture*
ALGS (n = 49) CIC (n = 41)
n Mean (SD) P† n Mean (SD) P†
BMD
Total body minus head 0.07 0.33
Bone fracture 19 –0.3 (1.8) 10 –0.8 (1.7)
No bone fracture 29 0.6 (1.5) 30 –0.2 (1.4)
Spine 0.02 0.12
Bone fracture 19 –0.6 (1.7) 10 –1.6 (1.0)
No bone fracture 29 0.6 (1.4) 30 –1.0 (0.9)
Total hip 0.21
Bone fracture 18 –0.8 (1.6) 10 –1.5 (1.5) 0.41
No bone fracture 28 –0.2 (1.3) 29 –1.1 (1.2)
BMC
Total body minus head 0.02 0.96
Bone fracture 19 –0.2 (1.4) 10 –0.8 (1.2)
No bone fracture 29 0.7 (1.2) 30 –0.8 (1.2)
Lab measures
TB 0.03 0.89
Bone fracture 17 6.1 (6.8) 9 1.5 (1.4)
No bone fracture 25 2.0 (2.7) 29 1.6 (2.1)
SBA 0.02 0.58
Bone fracture 19 156.9 (119.2) 8 87.6 (95.7)
No bone fracture 20 79.7 (77.9) 26 64.3 (105.3)
*Bone fracture could have occurred before or after the DXA scan.
†P value based on two-sample t test.
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Although the ALGS and CIC participants were 
similar with respect to weight, height, and BMI Z 
scores, only the ALGS group showed a significant 
normalization of DXA Z scores after anthropomet-
ric adjustment. The reasons underlying this divergent 
phenotype are not entirely clear but are likely to be 
multifactorial. Individuals with ALGS are at risk of 
growth delay associated with the multisystem involve-
ment of the disease and the underlying genetic defect 
in Notch pathway signaling. Both ALGS and CIC 
patients can have profound cholestasis that would be 
expected to impact absorption of nutrients to a simi-
lar extent. A subset of CIC patients, specifically those 
with mutations in ATP8B1, may have intestinal man-
ifestations that could further contribute to malabsorp-
tion. Cytokine and immune-mediated alterations may 
also contribute to bone mineral deficits in patients 
with chronic cholestatic liver disease. One study of 
16 pediatric patients with biliary atresia, ALGS, and 
PFIC found elevated circulating levels of interleu-
kin-8, which correlated with severity of hepatic fibro-
sis.(20) In addition, immune dysregulation has been 
reported in ALGS as a result of altered cluster of 
differentiation 46–Notch pathway crosstalk.(21,22) In 
our study, we did not measure levels of inflammatory 
cytokines that could have a potential impact on bone 
health in this patient population. Further studies will 
be required to determine the etiology of persistent 
bone mineral deficits in the CIC cohort after adjust-
ment for patient size.
One of the key findings in this study is the strong 
correlation between weight-adjusted and height-ad-
justed DXA Z scores and laboratory measures of 
cholestasis and liver synthetic function, specifically in 
ALGS (Table 4). Similar correlations were not identi-
fied in the CIC group. Notably, OH vitamin D levels 
were not correlated with DXA Z scores in this choles-
tatic population. The effect of cholestasis on bone 
metabolism has been studied both in vitro and in 
vivo. Ruiz-Gaspà et al. treated human primary osteo-
blasts with bilirubin or serum from jaundiced patients 
and found decreased osteoblast viability and differen-
tiation, reduced expression of osteogenic transcription 
factors, and up-regulation of factors inducing osteo-
clastogenesis.(23) Histomorphometric analysis of 50 
patients with PBC and PSC at the time of liver trans-
plantation showed decreased bone formation in both 
male and female patients and increased bone resorp-
tion only in female patients.(24) These studies support 
the hypothesis that cholestasis has direct effects on 
bone remodeling. The divergent results for the ALGS 
and CIC groups with respect to correlations between 
DXA measures and cholestasis are not well under-
stood but may be explained to some extent by the fact 
that ALGS participants in this study had higher mean 
TB and SBA levels compared with the CIC group. 
However, the majority of the CIC participants (56%) 
had undergone biliary diversion, indicating a history 
of long-standing and profound cholestasis at some 
point in the past, which is unlikely to be reflected by 
current laboratory values. Varying clinical response to 
biliary diversion, ranging from complete resolution 
of cholestasis to ongoing issues with fat-soluble vita-
min deficiencies, complicates interpretation of these 
results.
ALGS is an autosomal dominant disorder caused 
by mutations in the Notch ligand JAGGED1 (JAG1) 
gene in >90% of cases, with mutations in NOTCH2 
found in a small percentage of patients.(25,26) JAG1 
encodes the Jagged1 ligand in the Notch signaling 
pathway, which is essential for cell fate decisions in 
multiple tissues and cell types, accounting for the 
multisystem involvement in ALGS.(27) Skeletal 
anomalies, primarily facial dysmorphism and butter-
fly vertebrae, are well-recognized clinical features of 
ALGS. Interestingly, a genome-wide association study 
in Chinese women identified a single-nucleotide 
polymorphism (SNP) in the JAG1 gene to have a pro-
tective effect on BMD and osteoporotic fractures.(28) 
The risk SNP was found to increase JAG1 expression 
in human bone-derived cells. This finding, which has 
now been replicated in other ethnic cohorts, indicates 
a role for JAG1 and Notch signaling in bone homeo-
stasis. Additional studies support an important func-
tion for Notch signaling in skeletal development, as 
well as postnatal bone maintenance and remodeling. 
Data derived from animal models suggest that the 
underlying genetic defect in ALGS may lead to struc-
tural abnormalities of the cortical and trabecular bone, 
which may not be adequately characterized by DXA 
analysis.(29-31)
In this study, weight-adjusted and height-adjusted 
DXA Z scores were lower in ALGS and CIC par-
ticipants who had fractures compared to those who 
did not, and TB and SBAs were higher in the ALGS 
fracture group (Table 5). In ALGS, but not in CIC, 
differences in DXA measures in participants with 
a history of fracture reached a marginal statistical 
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significance. It is unclear why DXA measures would 
be lower in ALGS patients with a fracture history 
and not in CIC; it is possible that Notch signaling 
deficits play a prominent role in fracture development 
separate from the severity of cholestasis in ALGS. In 
this case, the CIC cohort would be an ideal choles-
tatic control population for study of this relationship. 
However, variable timing of bone fracture and biliary 
diversion complicates interpretation of the DXA data 
in the CIC group. In healthy children, there is evi-
dence that bone mass is lower in those with a fracture 
history. BMC and areal BMD measures were lower 
at all body sites in normal children who had sus-
tained fractures compared with those who had not.(32) 
Modest decreases in bone mass have been observed 
in children with a fracture history.(33) Previous stud-
ies have shown increased fracture vulnerability in 
ALGS. In a cohort of ALGS patients, 12 of 42 (28%) 
reported 27 fractures,(4) which occurred at a young 
age, predominantly in the lower extremities and with 
minimal trauma. Femur fractures were 50 times more 
likely than expected for the general population.(4) The 
modest differences in DXA Z scores identified in 
our ALGS cohort do not provide an explanation for 
predisposition to pathologic fracture in ALGS. The 
genetic underpinnings of ALGS may lead to intrinsic 
abnormalities of bone strength and composition that 
are underestimated by DXA imaging techniques.
In this study, we found no statistically significant 
differences in height-adjusted and weight-adjusted 
DXA Z scores between participants with and without 
biliary diversion. Variable clinical response to biliary 
diversion significantly complicates the interpretation 
of the results of these analyses.(34) Some patients may 
respond to biliary diversion with normalization of bil-
irubin and bile acids, but low intestinal luminal bile 
acid levels may lead to profound fat-soluble vitamin 
deficiencies. Limited numbers of participants who 
underwent biliary diversion precluded subanalysis 
of bile flow after the procedure with regard to clin-
ical response and vitamin D status. After successful 
drainage procedures, some patients develop bouts of 
cholestasis that can last months, akin to benign recur-
rent intrahepatic cholestasis.(35) As such, the timing 
of DXA scanning relative to intermittent cholestasis 
events could affect the DXA findings.
Our study has some limitations. Because our study 
is cross-sectional in design, it was not possible to 
correlate bone mineral deficits with progression or 
improvement of underlying liver disease. Given that 
these inherited pediatric liver disorders are all quite 
rare, population sizes were limited and did not allow 
for multiple comparisons. In addition, only 40% of 
eligible ALGS participants and 51% of eligible CIC 
participants underwent DXA analysis. Within the 
CIC cohort, small numbers precluded subanalysis of 
the specific genetic etiology of liver disease. This was 
especially true in the analysis of those individuals with 
biliary diversion. In this group, it would have been 
ideal to subdivide the patients by level of cholestasis 
and vitamin D sufficiency, but this was not possible 
due to limited numbers of participants.
In conclusion, our results represent the largest 
study, to date, of DXA analysis in a well-characterized 
cohort of children with intrahepatic cholestatic liver 
diseases. In particular, children with ALGS and CIC 
have significant bone mineral deficits that can impact 
clinical outcomes. There are clearly complex and 
poorly understood multifactorial influences on bone 
mineralization in this population, with varying effects 
on growth, degree of cholestasis, fracture vulnerabil-
ity, and direct contribution of underlying genetic eti-
ology. Fractures in this population are unlikely to be 
simple manifestations of vitamin D deficiency but are 
the result of a much more complex pathophysiology. 
Further studies will be required to fully character-
ize bone health in this unique patient population, to 
develop methods to predict patients at high risk for 
fracture, and to generate new approaches to prevent 
those fractures.
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